|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01177 SINO BIOPHARM
Nominal 
8.170 +0.450 (+5.829%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | |
| Turnover | 17,574,778 | 10.711% | 15,874,403 | 15,277,037 | 15,193,738 | 14,353,781 |
| Cost of Sales | (3,081,084) | 8.307% | (2,844,780) | (3,256,505) | (2,959,599) | (2,753,121) |
| Gross Profit | 14,493,694 | 11.236% | 13,029,623 | 12,020,532 | 12,234,139 | 11,600,660 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (4,823) | -94.817% | (93,056) | (219,438) | 503,155 | 7,584,980 | |
| Profit / (Loss) before Taxation | 5,966,963 | 65.106% | 3,614,016 | 3,224,167 | 3,754,612 | 10,978,515 | |
| Taxation | (981,324) | 59.801% | (614,093) | (524,743) | (571,391) | (1,336,911) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | 1,606,765 | -- | -- | -- | |
| Non-controlling Interests | (1,597,048) | 0.473% | (1,589,526) | (1,440,640) | (1,262,184) | (1,161,264) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,388,591 | 12.311% | 3,017,162 | 1,258,784 | 1,921,037 | 8,480,340 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | |
| Net Finance Costs / (Income) | (250,372) | 257.118% | (70,109) | 115,037 | 46,423 | 47,914 |
| Depreciation & Amortisation | 575,692 | 12.830% | 510,231 | 653,208 | 408,672 | 413,156 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/06 | 2023/06 | 2022/06 | 2021/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/06 | 2023/06 | 2022/06 | 2021/06 | |
| EPS (cts) | 18.820 | 14.826% | 16.390 | 6.780 | 10.300 | 45.150 |
| DPS (cts) | 4.562 | -- | 2.752 | 1.833 | 5.229 | 3.323 |
| Dividend Payout Ratio (%) | 24.242% | -- | 16.792% | 27.036% | 50.769% | 7.359% |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 1.779 | -- | 1.748 | 1.594 | 1.606 | 1.303 |
| Remarks: | Real time quote last updated: 22/08/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,388,591 |
| %Change | 12.311% |
| EPS / (LPS) | RMB 0.188 |
| NBV Per Share (¥) | RMB 1.779 |